{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:20:49Z","timestamp":1790256049169,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,18]],"date-time":"2017-01-18T00:00:00Z","timestamp":1484697600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.japh.2017.01.004","type":"journal-article","created":{"date-parts":[[2017,3,2]],"date-time":"2017-03-02T00:15:56Z","timestamp":1488413756000},"page":"303-310.e2","source":"Crossref","is-referenced-by-count":26,"title":["Medication adherence, molecular monitoring, and clinical outcomes in patients with chronic myelogenous leukemia in a large HMO"],"prefix":"10.1016","volume":"57","author":[{"given":"Reina","family":"Haque","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxiao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanie","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Avila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed A.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne E.","family":"Schottinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.japh.2017.01.004_bib1","author":"National Cancer Institute"},{"issue":"Suppl 2","key":"10.1016\/j.japh.2017.01.004_bib2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2011.0125","article-title":"NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia","volume":"9","author":"O'Brien","year":"2011","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"23","key":"10.1016\/j.japh.2017.01.004_bib3","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.japh.2017.01.004_bib4","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ajh.22019","article-title":"Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia","volume":"86","author":"Ganesan","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.japh.2017.01.004_bib5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/978-1-4614-6176-0_8","article-title":"Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms","volume":"779","author":"Bisen","year":"2013","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.japh.2017.01.004_bib6","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.japh.2017.01.004_bib7","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.leukres.2010.10.017","article-title":"Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed","volume":"35","author":"Eliasson","year":"2011","journal-title":"Leuk Res"},{"issue":"22","key":"10.1016\/j.japh.2017.01.004_bib8","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.japh.2017.01.004_bib9","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","article-title":"Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy","volume":"117","author":"Ibrahim","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.japh.2017.01.004_bib10","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1185\/03007990903396469","article-title":"Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients","volume":"26","author":"Wu","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.japh.2017.01.004_bib11","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1185\/03007995.2013.812034","article-title":"Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib","volume":"29","author":"Goldberg","year":"2013","journal-title":"Curr Med Res Opin"},{"issue":"15","key":"10.1016\/j.japh.2017.01.004_bib12","article-title":"Types, frequency, and adherence of molecular tests in chronic myelogenous leukemia at chronic phase (CML-CP) in the US community setting","volume":"31","author":"Chen","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.japh.2017.01.004_bib13","first-page":"449","article-title":"Estimating medication persistency using administrative claims data","volume":"11","author":"Sikka","year":"2005","journal-title":"Am J Manag Care"},{"issue":"6","key":"10.1016\/j.japh.2017.01.004_bib14","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1524-4733.2009.00543.x","article-title":"Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia","volume":"12","author":"Karve","year":"2009","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.japh.2017.01.004_bib15","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1345\/aph.1K671","article-title":"Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication","volume":"43","author":"Martin","year":"2009","journal-title":"Ann Pharmacother"},{"issue":"6","key":"10.1016\/j.japh.2017.01.004_bib16","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2165\/00019053-200725060-00004","article-title":"Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia","volume":"25","author":"Darkow","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.japh.2017.01.004_bib17","author":"National Comprehensive Cancer Network"},{"issue":"8","key":"10.1016\/j.japh.2017.01.004_bib18","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0895-4356(97)00091-7","article-title":"Calculating Charlson comorbidity index when analyzing short-term mortality using administrative data","volume":"50","author":"Cleves","year":"1997","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.japh.2017.01.004_bib19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1524-4733.2006.00139.x","article-title":"A\u00a0checklist for medication compliance and persistence studies using retrospective databases","volume":"10","author":"Peterson","year":"2007","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.japh.2017.01.004_bib20","doi-asserted-by":"crossref","first-page":"389","DOI":"10.5581\/1516-8484.20130120","article-title":"Chronic myeloid leukemia: an overview of the determinants of effectiveness and therapeutic response in the first decade of treatment with imatinib mesylate in a Brazilian hospital","volume":"35","author":"Cid","year":"2013","journal-title":"Rev Bras Hematol Hemoter"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319117300043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319117300043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T18:51:47Z","timestamp":1536000707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319117300043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S1544319117300043"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2017.01.004","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]}}}